President Donald Trump will nominate Dr. Heidi Overton to serve as the next commissioner of the U.S. Food and Drug Administration.
The appointment comes as the agency faces significant instability and staffing gaps. The FDA is currently grappling with concerns over drug-development stability, public trust, and the future direction of vaccine policy.
Overton currently serves as the deputy director of the Domestic Policy Council. Her transition from the White House to the regulatory agency is intended to provide leadership to an organization that has been in turmoil for several months.
The leadership vacancy began when former commissioner Marty Makary resigned in May 2026 [1]. This departure left the agency without a permanent head during a critical period of regulatory oversight.
Overton's nomination aims to resolve the current leadership void. The FDA oversees the safety and efficacy of human drugs, biological products, and the nation's food supply, roles that have faced increased scrutiny during the recent transition.
Because Overton has served as a high-level aide within the administration, she is expected to align the agency's operations with the current executive branch's domestic priorities. The nomination must now move through the standard confirmation process before she can officially assume the role of commissioner.
“President Donald Trump will nominate Dr. Heidi Overton to serve as the next commissioner of the U.S. Food and Drug Administration.”
The selection of a White House insider to lead the FDA suggests an effort by the administration to exert tighter control over regulatory processes. By appointing a deputy director from the Domestic Policy Council, the administration may be seeking to accelerate specific policy changes regarding vaccine distribution and drug approvals that were stalled following the May resignation of Marty Makary.
